--- title: "Public Policy (LON:PPHC) Shares Down 1.1% - Here's What Happened" description: "Public Policy Holding Company (LON:PPHC) shares fell 1.1% to GBX 880 during mid-day trading, with a trading volume decline of 67% from the average. The company's 50-day and 200-day simple moving avera" type: "news" locale: "en" url: "https://longbridge.com/en/news/275416811.md" published_at: "2026-02-10T07:18:28.000Z" --- # Public Policy (LON:PPHC) Shares Down 1.1% - Here's What Happened > Public Policy Holding Company (LON:PPHC) shares fell 1.1% to GBX 880 during mid-day trading, with a trading volume decline of 67% from the average. The company's 50-day and 200-day simple moving averages are GBX 1,043.18 and GBX 1,007.37, respectively. PPHC has a market cap of £251.51 million and a price-to-earnings ratio of 10.35. Despite a Buy rating from analysts, it was not included in a list of top stock recommendations. Public Policy Holding Company, Inc. (LON:PPHC - Get Free Report)'s share price fell 1.1% during mid-day trading on Monday . The company traded as low as GBX 880 and last traded at GBX 880. 6,112 shares changed hands during trading, a decline of 67% from the average session volume of 18,479 shares. The stock had previously closed at GBX 890. Get **Public Policy** alerts: ## Public Policy Trading Down 1.1% The company's 50 day simple moving average is GBX 1,043.18 and its 200 day simple moving average is GBX 1,007.37. The company has a debt-to-equity ratio of 73.20, a current ratio of 1.07 and a quick ratio of 1.88. The firm has a market cap of £251.51 million and a price-to-earnings ratio of 10.35. ## About Public Policy (Get Free Report) Public Policy Holding Company (PPHC) is a leading bi-partisan full-service U.S. government and public affairs business based in Washington DC. Working with over 1000 clients, including corporates, trade associations and non-governmental organisations, the Group is active in all major sectors of the U.S. economy, including healthcare and pharmaceuticals, financial services, energy, technology, telecoms and transportation. PPHC's companies work to enhance and defend clients' reputations, advance policy goals, manage regulatory risk, and engage with US federal and state-level policy makers, stakeholders, media and the public. ## Read More - Five stocks we like better than Public Policy - The buying spree that no one is talking about - How to collect $500-$800 weekly (BlackRock's system) - Trump’s AI Secret: 100X Faster Than Nvidia - NEW LAW: Congress Approves Setup For Digital Dollar? - Your Bank Account Is No Longer Safe *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Public Policy Right Now? Before you consider Public Policy, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Public Policy wasn't on the list. While Public Policy currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [PPHC.US - Public Policy](https://longbridge.com/en/quote/PPHC.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say | Indian drugmaker Dr Reddy's Laboratories is set to launch its generic semaglutide injection, branded as Obeda, in March | [Link](https://longbridge.com/en/news/276858725.md) | | Boston Beer Co Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | Boston Beer Co (NYSE:SAM) has received mixed evaluations from 4 analysts over the past three months, with an average 12- | [Link](https://longbridge.com/en/news/276938233.md) | | Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead | Corbus Pharmaceuticals (NASDAQ:CRBP) announced a "catalyst-rich" 2026 at Oppenheimer’s Healthcare Conference, highlighti | [Link](https://longbridge.com/en/news/277003496.md) | | A wake for The Washington Post’s books section | Hundreds gathered in Washington, DC, to mourn the closure of The Washington Post's Book World section, which was recentl | [Link](https://longbridge.com/en/news/276785250.md) | | Ireland's Jazz Pharmaceuticals beats Q4 revenue, profit estimates | Ireland's Jazz Pharmaceuticals reported a 10% year-over-year increase in Q4 revenue, surpassing analyst expectations. Th | [Link](https://longbridge.com/en/news/276790815.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.